{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:20:44Z","timestamp":1773073244413,"version":"3.50.1"},"reference-count":30,"publisher":"Japanese Society of Hypertension","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2006]]},"DOI":"10.1291\/hypres.29.211","type":"journal-article","created":{"date-parts":[[2006,6,16]],"date-time":"2006-06-16T05:52:35Z","timestamp":1150437155000},"page":"211-216","source":"Crossref","is-referenced-by-count":49,"title":["Combination Therapy with Aldosterone Blockade and Renin-Angiotensin Inhibitors Confers Organ Protection"],"prefix":"10.1291","volume":"29","author":[{"given":"Atsuhisa","family":"SATO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"SARUTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"FUNDER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pitt B, Zannad F, Remme WJ, <i>et al<\/i>, for the Randomized Aldactone Evaluation Study: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. <i>N Engl J Med<\/i> 1999; <b>341<\/b>: 709-717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Juurlink DN, Mamdani MM, Lee DS, <i>et al<\/i>: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. <i>N Engl J Med<\/i> 2004; <b>351<\/b>: 543-551.","DOI":"10.1056\/NEJMoa040135"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sligl W, McAlister FA, Ezekowitz J, Armstrong PW: Usefulness of spironolactone in a specialized heart failure clinic. <i>Am J Cardiol<\/i> 2004; <b>94<\/b>: 443-447.","DOI":"10.1016\/j.amjcard.2004.04.059"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Greenberg B: Treatment of heart failure: state of the art and prospectives. <i>J Cardiovasc Pharmacol<\/i> 2002; <b>38<\/b>: 59-63.","DOI":"10.1097\/00005344-200111002-00015"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Remme WJ, Swedberg K: Comprehensive guideline for the diagnosis and treatment of chronic heart failure. <i>Eur J Heart Fail<\/i> 2002; <b>4<\/b>: 11-22.","DOI":"10.1016\/S1388-9842(01)00231-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rocha R, Funder JW: The pathophysiology of aldosterone in the cardiovascular system. <i>Ann N Y Acad Sci<\/i> 2002; <b>970<\/b>: 89-100.","DOI":"10.1111\/j.1749-6632.2002.tb04415.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Young M, Head G, Funder JW: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. <i>Am J Physiol<\/i> 1995; <b>269<\/b>: 657-662.","DOI":"10.1152\/ajpendo.1995.269.4.E657"},{"key":"9","unstructured":"9. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium and myocardial fibrosis. <i>J Lab Clin Med<\/i> 1992; <b>120<\/b>: 893-901."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Funder JW: Aldosterone, salt and cardiac fibrosis. <i>Clin Exp Hypertens<\/i> 1997; <b>19<\/b>: 885-899.","DOI":"10.3109\/10641969709083193"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.303"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Funder JW: Is aldosterone bad for the heart? <i>Trends Endocrinol Metab<\/i> 2004; <b>15<\/b>: 139-142.","DOI":"10.1016\/j.tem.2004.03.006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sato A, Suzuki Y, Saruta T: Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. <i>Hypertens Res<\/i> 1999; <b>22<\/b>: 17-27.","DOI":"10.1291\/hypres.22.17"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sato A, Saruta T: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. <i>J Int Med Res<\/i> 2001; <b>29<\/b>: 13-21.","DOI":"10.1177\/147323000102900103"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(03)00913-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. van Vliet AA, Donker AJM, Nauta JJP, Verheugt FWA: Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. <i>Am J Cardiol<\/i> 1993; <b>71<\/b>: 21A-28A.","DOI":"10.1016\/0002-9149(93)90241-4"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80353-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fung JWH, Yu CM, Yip G, <i>et al<\/i>: Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. <i>Am J Cardiol<\/i> 2003; <b>92<\/b>: 406-410.","DOI":"10.1016\/S0002-9149(03)00658-1"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091405.00772.6E"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. <i>Am J Hypertens<\/i> 2005; <b>18<\/b>: 44-49.","DOI":"10.1016\/j.amjhyper.2004.06.029"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091234.45664.62"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. McKlelvie RS, Yusuf S, Mmath P, <i>et al<\/i>, The RESOLVD Pilot Study Investigators: Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. <i>Circulation<\/i> 1999; <b>100<\/b>: 1056-1064.","DOI":"10.1161\/01.CIR.100.10.1056"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Azizi M, Menard J: Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. <i>Circulation<\/i> 2004; <b>109<\/b>: 2492-2499.","DOI":"10.1161\/01.CIR.0000131449.94713.AD"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. <i>J Am Coll Cardiol<\/i> 2003; <b>41<\/b>: 211-214.","DOI":"10.1016\/S0735-1097(02)02694-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D: Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. <i>BMJ<\/i> 2003; <b>327<\/b>: 1141-1142.","DOI":"10.1136\/bmj.327.7424.1141"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. <i>BMJ<\/i> 2003; <b>327<\/b>: 147-149.","DOI":"10.1136\/bmj.327.7407.147"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. <i>Am J Med<\/i> 2001; <b>110<\/b>: 438-441.","DOI":"10.1016\/S0002-9343(01)00642-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tamirisa KP, Aaronson KD, Koelling TM: Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. <i>Am Heart J<\/i> 2004; <b>148<\/b>: 971-978.","DOI":"10.1016\/j.ahj.2004.10.005"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T11:20:27Z","timestamp":1555672827000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nature.com\/doifinder\/10.1291\/hypres.29.211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.29.211","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}